col blocks we are bridge builder col blocks
COVID Antworten in den wissenschaftlichen Zeitschriften der Welt


58 Ergebisse       Seite 1

 [1] 
Elsevier: Acta Pharmaceutica Sinica B
  Original Artikel Datum Titel Autoren   Alle Autoren
1 [GO] 2025―Jan―01 A retrospective cohort study of the efficacy and safety of oral azvudine versus nirmatrelvir/ritonavir in elderly hospitalized COVID-19 patients aged over 60 years Bo Yu, Haiyu Wang, Guangming Li, Junyi Sun, Hong Luo, Mengzhao Yang, et al. (+12)
2 [GO] 2024―Dez―30 Boosting with Omicron-specific mRNA vaccine or historical SARS-CoV-2 vaccines elicits discriminating immune responses against Omicron variants Yi Wu, Xiaoying Jia, Namei Wu, Xinghai Zhang, Yan Wu, Yang Liu, et al. (+7)
3 [GO] 2024―Dez―12 Real-world efficacy and safety of azvudine in hospitalized older patients with COVID-19 during the omicron wave in China: A retrospective cohort study Yuanchao Zhu, Fei Zhao, Yubing Zhu, Xingang Li, Deshi Dong, Bolin Zhu, et al. (+49)
4 [GO] 2024―Dez―07 Protection efficacy of mRNA-based SARS-CoV-2 variant vaccine in non-human primates Dongrong Yi, Yongxin Zhang, Jing Wang, Qian Liu, Ling Ma, Quanjie Li, et al. (+9)
5 [GO] 2024―Jul―06 Jun12682, a potent SARS-CoV-2 papain-like protease inhibitor with exceptional antiviral efficacy in mice Mianling Yang, Meehyein Kim, Peng Zhan
6 [GO] 2024―Mai―31 Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics Chris Chun-Yiu Chan, Qian Guo, Jasper Fuk-Woo Chan, Kaiming Tang, Jian-Piao Cai, Kenn Ka-Heng Chik, et al. (+22)
7 [GO] 2024―Mai―22 SARS-CoV-2 ORF10 hijacking ubiquitination machinery reveals potential unique drug targeting sites Kaixiang Zhu, Lili Song, Linyue Wang, Lei Hua, Ziyu Luo, Tongyun Wang, et al. (+5)
8 [GO] 2024―Apr―15 Discovery and characterization of novel potent non-covalent small molecule inhibitors targeting papain-like protease from SARS-CoV-2 Miao Zheng, Bo Feng, Yumin Zhang, Xin Liu, Na Zhao, Hui Liu, et al. (+13)
9 [GO] 2024―Mrz―12 Ciclopirox inhibits SARS-CoV-2 replication by promoting the degradation of the nucleocapsid protein Xiafei Wei, Yuzheng Zhou, Xiaotong Shen, Lujie Fan, Donglan Liu, Xiang Gao, et al. (+5)
10 [GO] 2024―Mrz―06 Development of an active-site titrant for SARS-CoV-2 main protease as an indispensable tool for evaluating enzyme kinetics Rabea Voget, Julian Breidenbach, Tobias Claff, Alexandra Hingst, Katharina Sylvester, Christian Steinebach, et al. (+6)
11 [GO] 2024―Mrz―03 Carrimycin inhibits coronavirus replication by decreasing the efficiency of programmed -1 ribosomal frameshifting through directly binding to the RNA pseudoknot of viral frameshift-stimulatory element Hongying Li, Jianrui Li, Jiayu Li, Hu Li, Xuekai Wang, Jing Jiang, et al. (+12)
12 [GO] 2024―Feb―13 Bile acids and coronavirus disease 2019 Xiaoru Huang, Xuening Liu, Zijian Li
13 [GO] 2023―Aug―25 Immunogenicity of mucosal COVID-19 vaccine candidates based on the highly attenuated vesicular stomatitis virus vector (VSVMT) in golden syrian hamster Yong Ke, En Zhang, Jianming Guo, Xiaoxiao Zhang, Lei Wang, Duo Chen, et al. (+5)
14 [GO] 2023―Aug―09 Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors Letian Song, Shenghua Gao, Bing Ye, Mianling Yang, Yusen Cheng, Dongwei Kang, et al. (+6)
15 [GO] 2023―Aug―08 Corrigendum to Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles Canhao Wu, Qin Xu, Huiyuan Wang, Bin Tu, Jiaxin Zeng, Pengfei Zhao, et al. (+3)
16 [GO] 2023―Jul―13 Clinical Trials Azvudine reduces the in-hospital mortality of COVID-19 patients: A retrospective cohort study Kaican Zong, Hui Zhou, Wen Li, E. Jiang, Yi Liu, Shiying Li
17 [GO] 2023―Mai―27 HR121 targeting HR2 domain in S2 subunit of spike protein can serve as a broad-spectrum SARS-CoV-2 inhibitor via intranasal administration Ying Lu, Fan Shen, Wenqiang He, Anqi Li, Minghua Li, Xiaoli Feng, et al. (+2)
18 [GO] 2023―Apr―18 SARS-CoV-2 spike host cell surface exposure promoted by a COPI sorting inhibitor Yiqun Li, Mingrui Yang, Yanan Nan, Jiaming Wang, Sanjiao Wang, Dongxiao Cui, et al. (+6)
19 [GO] 2023―Feb―24 Application of microfluidic technologies on COVID-19 diagnosis and drug discovery Zhun Lin, Zhengyu Zou, Zhe Pu, Minhao Wu, Yuanqing Zhang
20 [GO] 2023―Feb―23 A micro-sized vaccine based on recombinant Lactiplantibacillus plantarum fights against SARS-CoV-2 infection via intranasal immunization Letian Li, Jiayi Hao, Yuhang Jiang, Pengfei Hao, Yuwei Gao, Jing Chen, et al. (+4)
21 [GO] 2023―Feb―21 Regulating the microenvironment with nanomaterials: Potential strategies to ameliorate COVID-19 Zhicheng Liu, Zhuolei Han, Xin Jin, Jusung An, Jaewon Kim, Wenting Chen, et al. (+3)
22 [GO] 2023―Feb―09 Can FXR serve as a potential target for COVID-19 prevention? Juan Pang, Jia Nuo Feng, Wenhua Ling, Tianru Jin
23 [GO] 2023―Jan―12 A novel heterologous receptor-binding domain dodecamer universal mRNA vaccine against SARS-CoV-2 variants Shugang Qin, Hai Huang, Wen Xiao, Kepan Chen, Xi He, Xiaoshan Tang, et al. (+10)
24 [GO] 2022―Nov―21 Mucosal delivery of nanovaccine strategy against COVID-19 and its variants Junwoo Lee, Dongwoo Khang
25 [GO] 2022―Sep―23 Localized delivery of nanomedicine and antibodies for combating COVID-19 Bin Tu, Yanrong Gao, Xinran An, Huiyuan Wang, Yongzhuo Huang
26 [GO] 2022―Aug―09 Schaftoside inhibits 3CLpro and PLpro of SARS-CoV-2 virus and regulates immune response and inflammation of host cells for the treatment of COVID-19 Yang Yi, Meng Zhang, Heng Xue, Rong Yu, Yang-Oujie Bao, Yi Kuang, et al. (+14)
27 [GO] 2022―Jul―22 Single-shot AAV-vectored vaccine against SARS-CoV-2 with fast and long-lasting immunity Fuhua Wu, Shuang Luo, Yongshun Zhang, Yangsen Ou, Hairui Wang, Zhaofei Guo, et al. (+7)
28 [GO] 2022―Jun―09 Acrylamide fragment inhibitors that induce unprecedented conformational distortions in enterovirus 71 3C and SARS-CoV-2 main protease Bo Qin, Gregory B. Craven, Pengjiao Hou, Julian Chesti, Xinran Lu, Emma S. Child, et al. (+6)
29 [GO] 2022―Jun―06 Rapid screening of SARS-CoV-2 inhibitors via ratiometric fluorescence of RBD-ACE2 complexes in living cells by competitive binding Lu Miao, Wei Zhou, Chunyu Yan, Yuebin Zhang, Qinglong Qiao, Xuelian Zhou, et al. (+11)
30 [GO] 2022―Apr―08 Viral miRNA-mediated activation of hyaluronan production as a drug target against COVID-19 Shuai Yang, Lu Chen, Ying Tong, Wenqiang Yu
31 [GO] 2022―Feb―28 Suppressing fatty acid synthase by type I interferon and chemical inhibitors as a broad spectrum anti-viral strategy against SARS-CoV-2 Saba R. Aliyari, Amir Ali Ghaffari, Olivier Pernet, Kislay Parvatiyar, Yao Wang, Hoda Gerami, et al. (+12)
32 [GO] 2022―Feb―11 Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants Bin Tu, Huiyuan Wang, Xinran An, Jingkun Qu, Qianqian Li, Yanrong Gao, et al. (+3)
33 [GO] 2021―Nov―01 Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays Chunlong Ma, Haozhou Tan, Juliana Choza, Yuying Wang, Jun Wang
34 [GO] 2021―Sep―20 Traditional Chinese medicine in COVID-19 Ming Lyu, Guanwei Fan, Guangxu Xiao, Taiyi Wang, Dong Xu, Jie Gao, et al. (+9)
35 [GO] 2021―Sep―09 Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles Canhao Wu, Qin Xu, Huiyuan Wang, Bin Tu, Jiaxin Zeng, Pengfei Zhao, et al. (+3)
36 [GO] 2021―Aug―31 Medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitors Shenghua Gao, Tianguang Huang, Letian Song, Shujing Xu, Yusen Cheng, Srinivasulu Cherukupalli, et al. (+6)
37 [GO] 2021―Aug―02 A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases Jie Zhou, Wei Xu, Zezhong Liu, Chao Wang, Shuai Xia, Qiaoshuai Lan, et al. (+8)
38 [GO] 2021―Jul―02 Recent advances in developing small-molecule inhibitors against SARS-CoV-2 Rong Xiang, Zhengsen Yu, Yang Wang, Lili Wang, Shanshan Huo, Yanbai Li, et al. (+6)
39 [GO] 2021―Mai―13 SARS-CoV-2 cell entry and targeted antiviral development Zinuo Chen, Ruikun Du, Jazmin M. Galvan Achi, Lijun Rong, Qinghua Cui
40 [GO] 2021―Mrz―12 Repurposing CFDA-approved drug carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2 Haiyan Yan, Jing Sun, Kun Wang, Huiqiang Wang, Shuo Wu, Linlin Bao, et al. (+17)
41 [GO] 2021―Feb―16 Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase Quanjie Li, Dongrong Yi, Xiaobo Lei, Jianyuan Zhao, Yongxin Zhang, Xiangling Cui, et al. (+11)
42 [GO] 2020―Nov―16 Neutralizing antibodies for the treatment of COVID-19 Zeqi Zhou, Xiangbin Wang, Yankai Fu, Xiqing Zhang, Changxiao Liu
43 [GO] 2020―Okt―13 Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator Jingwei Bian, Zijian Li
44 [GO] 2020―Sep―07 Letter to the Editor: Increased plasma ACE2 concentration does not mean increased risk of SARS-CoV-2 infection and increased fatality rate of COVID-19 Xue-Ting Li, Ying Liu, Juan-Juan Song, Jiu-Chang Zhong
45 [GO] 2020―Sep―02 Crystal structure of SARS-CoV-2 papain-like protease Xiaopan Gao, Bo Qin, Pu Chen, Kaixiang Zhu, Pengjiao Hou, Justyna Aleksandra Wojdyla, et al. (+2)
46 [GO] 2020―Aug―18 Editor Profiles: Guest Editors of Special Column “Research on Emerging COVID-19 (Target, Mechanism, and Therapeutics)”
47 [GO] 2020―Aug―18 Editorial of Special Column “Research on Emerging COVID-19 (Target, Mechanism, and Therapeutics)” Hai-Bin Luo, Shilin Chen, Peiqing Liu
48 [GO] 2020―Jun―27 Combating COVID-19 with integrated traditional Chinese and Western medicine in China Liqiang Ni, Weian Yuan, Lili Chen, Chouping Han, Hong Zhang, Xin Luan, et al. (+3)
49 [GO] 2020―Jun―08 Bioactive natural compounds against human coronaviruses: a review and perspective Yanfang Xian, Juan Zhang, Zhaoxiang Bian, Hua Zhou, Zhenbiao Zhang, Zhixiu Lin, Hongxi Xu
50 [GO] 2020―Mai―30 Highly pathogenic coronaviruses: thrusting vaccine development in the spotlight Chunting He, Ming Qin, Xun Sun
51 [GO] 2020―Mai―27 Analysis on herbal medicines utilized for treatment of COVID-19 Lu Luo, Jingwen Jiang, Cheng Wang, Martin Fitzgerald, Weifeng Hu, Yumei Zhou, et al. (+2)
52 [GO] 2020―Mai―27 Letter to the Editor: Comment on GLP-1-based drugs and COVID-19 treatment Tianru Jin, Mingyao Liu
53 [GO] 2020―Apr―29 Anti-RAS drugs and SARS-CoV-2 infection Jingwei Bian, Rongsheng Zhao, Suodi Zhai, Zijian Li
54 [GO] 2020―Apr―21 Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites Sisi Kang, Mei Yang, Zhongsi Hong, Liping Zhang, Zhaoxia Huang, Xiaoxue Chen, et al. (+8)
55 [GO] 2020―Apr―20 Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19 Xiaoyan Liu, Zhe Li, Shuai Liu, Jing Sun, Zhanghua Chen, Min Jiang, et al. (+19)
56 [GO] 2020―Apr―20 D3Targets-2019-nCoV: a webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19 Yulong Shi, Xinben Zhang, Kaijie Mu, Cheng Peng, Zhengdan Zhu, Xiaoyu Wang, et al. (+3)
57 [GO] 2020―Apr―20 Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model Cheng Cui, Miao Zhang, Xueting Yao, Siqi Tu, Zhe Hou, Valerie Sia Jie En, et al. (+9)
58 [GO] 2020―Feb―27 Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods Canrong Wu, Yang Liu, Yueying Yang, Peng Zhang, Wu Zhong, Yali Wang, et al. (+7)
 [1] 

58 Ergebisse       Seite 1


[de][en]

Letzte Änderung 2023―Okt―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.004 sec